Journal
EXPERIMENTAL CELL RESEARCH
Volume 394, Issue 2, Pages -Publisher
ELSEVIER INC
DOI: 10.1016/j.yexcr.2020.112168
Keywords
beta-Thalassemia; Sickle-cell anemia; Fetal hemoglobin; Hydroxyurea; beta-YAC transgenic mice; gamma-Globin induction; Flow cytometry; Erythroid differentiation; Immunocytochemistry
Categories
Funding
- Higher Education Commission (HEC) Pakistan, Indigenous Ph.D. Fellowship Program [518-85647-2PS5-062 (50043409)]
Ask authors/readers for more resources
Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating beta-hemoglobinopathies like beta-thalassemia and sickle cell anemia by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but significant nonresponders and toxicity limit its clinical usefulness. This study relates preclinical investigation of Tenofovir disoproxil fumarate (TDF) as a potential HbF inducing agent, using human erythroleukemia cell line and a beta-YAC mouse model. Erythroid induction of K562 cells was studied by the benzidine/H2O2 reaction, total hemoglobin production was estimated by plasma hemoglobin assay kit, and gamma-globin gene expression by RT-qPCR, whereas, fetal hemoglobin production was estimated by flow cytometry and immunofluorescence microscopy. We observed significantly increased gamma- globin gene transcription and HbF expression mediated by TDF in K562 cells. Subsequent treatment of beta-YAC transgenic mice with TDF confirmed HbF induction in vivo through an increase in gamma-globin gene expression and in the percentage of HbF positive red blood cells. Moreover, TDF showed no cytotoxic effect at HbF inducing concentrations. These data support the potential development of TDF for the treatment of hematological disorders, including beta-thalassemia and sickle cell anemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available